Abstract
The current treatment of organophosphorus compounds induced intoxication consists of combined administration of anticholinergic drug, oxime reactivator and anticonvulsant. Oxime reactivators are causal treatment of organophosphorus intoxication and they are able to cleave OP moiety from the molecule of inhibited acetylcholinesterase. Unfortunately, none of the currently used oximes is sufficiently effective against all nerve agents and pesticides. Thus, finding of new potent acetylcholinesterase reactivators is necessary.
In this study, the reactivation efficacy of three series of novel bisquaternary reactivators with prop-1,3-diyl, but-1,4-diyl and but-2-ene-1,4-diyl linker against paraoxon inhibited acetylcholinesterase in vitro is presented. The obtained results were compared to the commercially used reactivators (pralidoxime, trimedoxime, obidoxime, methoxime, asoxime). Some newly prepared compounds showed promising ability of paraoxon in vitro reactivation, even in human attainable plasma concentrations. The structure-activity relationship for reactivators of paraoxon induced inhibition was determined.
Keywords: Acetylcholinesterase, Organophosphate, Paraoxon, Reactivator, Oxime, SAR
Letters in Drug Design & Discovery
Title:SAR Study on Reactivators of Ethyl-Paraoxon Inhibited Acetylcholinesterase
Volume: 9 Issue: 6
Author(s): Ondrej Holas, Kamil Musilek, Anna Horova, Veronika Opletalova and Kamil Kuca
Affiliation:
Keywords: Acetylcholinesterase, Organophosphate, Paraoxon, Reactivator, Oxime, SAR
Abstract: The current treatment of organophosphorus compounds induced intoxication consists of combined administration of anticholinergic drug, oxime reactivator and anticonvulsant. Oxime reactivators are causal treatment of organophosphorus intoxication and they are able to cleave OP moiety from the molecule of inhibited acetylcholinesterase. Unfortunately, none of the currently used oximes is sufficiently effective against all nerve agents and pesticides. Thus, finding of new potent acetylcholinesterase reactivators is necessary.
In this study, the reactivation efficacy of three series of novel bisquaternary reactivators with prop-1,3-diyl, but-1,4-diyl and but-2-ene-1,4-diyl linker against paraoxon inhibited acetylcholinesterase in vitro is presented. The obtained results were compared to the commercially used reactivators (pralidoxime, trimedoxime, obidoxime, methoxime, asoxime). Some newly prepared compounds showed promising ability of paraoxon in vitro reactivation, even in human attainable plasma concentrations. The structure-activity relationship for reactivators of paraoxon induced inhibition was determined.
Export Options
About this article
Cite this article as:
Holas Ondrej, Musilek Kamil, Horova Anna, Opletalova Veronika and Kuca Kamil, SAR Study on Reactivators of Ethyl-Paraoxon Inhibited Acetylcholinesterase, Letters in Drug Design & Discovery 2012; 9 (6) . https://dx.doi.org/10.2174/157018012800673083
DOI https://dx.doi.org/10.2174/157018012800673083 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
subject Index To Volume 2
Mini-Reviews in Medicinal Chemistry Biology and Chemistry of Sphingosine-Related Metabolites
Current Organic Chemistry Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry The 21st Century Form of Vitamin E - Tocotrienol
Current Pharmaceutical Design Evolving Concepts Concerning Cardiac β-Adrenoceptor Function in Heart Failure
Current Pharmaceutical Design Novel, Acidic CCR2 Receptor Antagonists: Lead Optimization
Letters in Drug Design & Discovery Histamine H3 Antagonists for Treatment of Cognitive Deficits in CNS Diseases
Current Topics in Medicinal Chemistry Performance of Feature Selection Methods
Current Genomics Phylogenetic Methods in Drug Discovery
Current Drug Discovery Technologies Therapeutic Monitoring of Plasma Digoxin for COVID-19 Patients Using a Simple UPLC-MS/MS Method
Current Pharmaceutical Analysis Patent Selections
Recent Patents on Inflammation & Allergy Drug Discovery Integrated Computational Analysis on Some Indolo-quinoline Derivatives for the Development of Novel Antiplasmodium Agents: CoMFA, Pharmacophore Mapping, Molecular Docking and ADMET Studies
Current Signal Transduction Therapy The Effects of Increased Glucose Level and Glycolysis on SARS CoV-2 Infection
Mini-Reviews in Medicinal Chemistry Kinases as Targets for ENaC Regulation
Current Molecular Pharmacology Myeloproliferative Neoplasms Including Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis, Chronic Neutrophilic Leukemia, and Myeloproliferative Neoplasm, Unclassifiable
Current Cancer Therapy Reviews Sex-Related Differences Linked to Depression Disorders and Chronic Inflammation Diseases in Nursing Shift Workers: An Expsloratory Multidimensional Literature Review
Endocrine, Metabolic & Immune Disorders - Drug Targets Herpesvirus Saimiri-Based Gene Delivery Vectors
Current Gene Therapy Design, Synthesis and Computational Studies of New Benzothiazole Substituted Quinazolines as Potential Antimicrobial Agents
Letters in Drug Design & Discovery Current Strategies and Future Directions in Classification and Treatment of Uterine Sarcomas
Current Cancer Therapy Reviews Post-Coronavirus Disease Mucormycosis: Predisposing Factors and Possible Treatment: A Narrative Review
Coronaviruses